Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
AVP
REST API REST API
Homo sapiens
AVP is differentially expressed in 139 experiments: 60 organism parts: hypothalamus, lung, ... (58 more);, 96 disease states: normal, acute promyelocytic leukemia, ... (94 more);, 39 cell types 89 cell lines 11 compound treatments and 64 other conditions.
Synonyms ADH, ARVP
Orthologs Avp (Mus musculus)   avpl (Danio rerio)   NEU2_BOVIN (Bos taurus)   oxtl (Danio rerio)   Avp (Rattus norvegicus)   Q8SPU9_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, neuropeptide hormone activity, stored secretory granule, elevation of cytosolic calcium ion concentration, protein binding, caspase inhibitor activity, extracellular space, generation of precursor metabolites and energy, positive regulation of cell proliferation, positive regulation of gene expression, locomotory behavior, negative regulation of apoptosis, social behavior, response to stress, extracellular region, receptor binding, cell-cell signaling, signal transducer activity, soluble fraction, negative regulation of female receptivity, grooming behavior, dendrite, positive regulation of cell growth, transmembrane transport, response to ethanol, signal transduction, negative regulation of caspase activity, protein kinase activity, negative regulation of transmission of nerve impulse, positive regulation of peptidyl-serine phosphorylation, neurohypophyseal hormone activity, protein kinase C signaling cascade, water transport, positive regulation of cAMP biosynthetic process, V1B vasopressin receptor binding, response to nicotine, V1A vasopressin receptor binding, sodium-independent organic anion transport, positive regulation of cellular pH reduction, penile erection, positive regulation of glutamate secretion, ERK1 and ERK2 cascade, maternal aggressive behavior, maternal behavior, negative regulation of release of cytochrome c from mitochondria, positive regulation of systemic arterial blood pressure, positive regulation of prostaglandin biosynthetic process, multicellular organismal water homeostasis, hyperosmotic salinity response, positive regulation of vasoconstriction, protein phosphorylation, response to organic cyclic compound, regulation of renal sodium excretion
InterPro Term Neurhyp_horm
Gene-Disease Assocation DIABETES INSIPIDUS, NEUROHYPOPHYSEAL
UniProt Accession Q9UEW6, P01185
Search EB-eye ENSG00000101200
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-AFMX-5, E-GEOD-803, E-GEOD-6573, E-MTAB-24, ... (17 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-1309, E-GEOD-19639, E-GEOD-22639, E-GEOD-2450, E-GEOD-24147, ... (18 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-3529
MCF-10A
2
E-TABM-420, E-GEOD-14990
NCIH2347
1
E-MTAB-37
NCIH1993
1
E-MTAB-37
NCIH720
1
E-MTAB-37
UMC11
1
E-MTAB-37
83 more value(s).


Cell type

studied in E-GEOD-10797, E-GEOD-18811, E-AFMX-5, E-MTAB-25, E-GEOD-3920, ... (24 experiments)

Factor Value U/D Experiments
plasma cell
2
E-MEXP-2360, E-GEOD-6691
neuroblastoma cell
1
E-MEXP-669
germ cell
1
E-MTAB-25
squamous cell carcinoma
1
E-GEOD-17347
macrophage
1
E-GEOD-3982
SCC
1
E-GEOD-19188
33 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1869, E-MEXP-2069, ... (28 experiments)

Factor Value U/D Experiments
acute promyelocytic leukemia
3
E-GEOD-1729, E-GEOD-995, E-MTAB-62
chronic lymphocytic leukemia
2
E-GEOD-6691, E-GEOD-2466
gastric carcinoma
2
E-GEOD-2685, E-MTAB-37
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
Emery-Dreifuss muscular dystrophy
1
1
E-GEOD-3307
Kaposi's sarcoma
1
E-MEXP-561
90 more value(s).


Compound treatment

studied in E-GEOD-3284, E-GEOD-412, E-GEOD-5824, E-MEXP-1335, E-GEOD-995, ... (7 experiments)

Factor Value U/D Experiments
glutamine
2
E-MEXP-941, E-MEXP-1335
none
1
2
E-GEOD-5824, E-GEOD-412, E-GEOD-995
estradiol
4
1
E-GEOD-20081
bacterial endotoxin
1
1
E-GEOD-3284
rapamycin
1
E-GEOD-5824
placebo
1
E-MEXP-1335
5 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

cd38
studied in E-GEOD-22601

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-16363, E-GEOD-21340

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21374, E-GEOD-1563, E-GEOD-16363 ... (5 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-3140, E-GEOD-4667, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89

Environmental stress
studied in E-GEOD-1643

Epiregulin elisa conc ng ml
studied in E-GEOD-5851

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023

Genotype
studied in E-GEOD-2466, E-MEXP-421, E-TABM-321, E-GEOD-17347

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1446, E-MEXP-2146

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-20194, E-GEOD-16716

Individual
studied in E-MTAB-197, E-TABM-325, E-MEXP-2069, E-TABM-666, E-GEOD-19519, ... (20 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12254, E-GEOD-980

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-1343

RNAi
studied in E-MEXP-1509, E-MEXP-101

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-MEXP-70

Sex
studied in E-GEOD-2466

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-22152, E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor size
studied in E-GEOD-6532

Processing time: 0.539 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM